362 related articles for article (PubMed ID: 33361394)
1. Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism.
Cai LY; Chen SJ; Xiao SH; Sun QJ; Ding CH; Zheng BN; Zhu XY; Liu SQ; Yang F; Yang YX; Zhou B; Luo C; Zhang X; Xie WF
Cancer Res; 2021 Feb; 81(4):860-872. PubMed ID: 33361394
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of proliferation and invasion in hepatocellular carcinoma cells by CBP/p300 histone acetyltransferase activity.
Inagaki Y; Shiraki K; Sugimoto K; Yada T; Tameda M; Ogura S; Yamamoto N; Takei Y; Ito M
Int J Oncol; 2016 Feb; 48(2):533-40. PubMed ID: 26676548
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
4. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
Bi L; Ren Y; Feng M; Meng P; Wang Q; Chen W; Jiao Q; Wang Y; Du L; Zhou F; Jiang Y; Chen F; Wang C; Tang B; Wang Y
Cancer Res; 2021 Apr; 81(8):2015-2028. PubMed ID: 33602787
[TBL] [Abstract][Full Text] [Related]
5. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
6. P300-dependent acetylation of histone H3 is required for epidermal growth factor receptor-mediated high-mobility group protein A2 transcription in hepatocellular carcinoma.
Liang C; Niu J; Wang X; Zhang ZS; Yang RH; Yao X; Liu FY; Li WQ; Pei SH; Sun H; Wang CJ; Fang D; Xie SQ
Cancer Sci; 2021 Feb; 112(2):679-690. PubMed ID: 33164305
[TBL] [Abstract][Full Text] [Related]
7. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
8. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma.
Xue X; Gao W; Sun B; Xu Y; Han B; Wang F; Zhang Y; Sun J; Wei J; Lu Z; Zhu Y; Sato Y; Sekido Y; Miao Y; Kondo Y
Oncogene; 2013 Mar; 32(13):1724-34. PubMed ID: 22614011
[TBL] [Abstract][Full Text] [Related]
9. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
10. Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53.
Di Leo L; Vegliante R; Ciccarone F; Salvatori I; Scimeca M; Bonanno E; Sagnotta A; Grazi GL; Aquilano K; Ciriolo MR
Oncogene; 2019 Mar; 38(11):1860-1875. PubMed ID: 30367149
[TBL] [Abstract][Full Text] [Related]
11. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1.
Hua S; Lei L; Deng L; Weng X; Liu C; Qi X; Wang S; Zhang D; Zou X; Cao C; Liu L; Wu D
Oncogene; 2018 Mar; 37(12):1624-1636. PubMed ID: 29335523
[TBL] [Abstract][Full Text] [Related]
12. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment.
Zheng X; Xu M; Yao B; Wang C; Jia Y; Liu Q
Cell Signal; 2016 Sep; 28(9):1314-1324. PubMed ID: 27297362
[TBL] [Abstract][Full Text] [Related]
13. P300/CBP-associated factor (PCAF) inhibits the growth of hepatocellular carcinoma by promoting cell autophagy.
Jia YL; Xu M; Dou CW; Liu ZK; Xue YM; Yao BW; Ding LL; Tu KS; Zheng X; Liu QG
Cell Death Dis; 2016 Oct; 7(10):e2400. PubMed ID: 27711074
[TBL] [Abstract][Full Text] [Related]
14. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
15. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib.
Zhang Y; Feng J; Mi Y; Fan W; Qin R; Mei Y; Jin G; Mao J; Zhang H
Drug Metab Dispos; 2024 May; 52(6):555-564. PubMed ID: 38565301
[TBL] [Abstract][Full Text] [Related]
17. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
Yin F; Feng F; Wang L; Wang X; Li Z; Cao Y
Cell Death Dis; 2019 Sep; 10(9):672. PubMed ID: 31511501
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
19. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
20. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
